Gemcitabine and betulinic acid co-encapsulated PLGA-PEG polymer nanoparticles for improved efficacy of cancer chemotherapy.


Journal

Materials science & engineering. C, Materials for biological applications
ISSN: 1873-0191
Titre abrégé: Mater Sci Eng C Mater Biol Appl
Pays: Netherlands
ID NLM: 101484109

Informations de publication

Date de publication:
May 2019
Historique:
received: 27 08 2018
revised: 28 11 2018
accepted: 07 01 2019
entrez: 1 3 2019
pubmed: 1 3 2019
medline: 14 6 2019
Statut: ppublish

Résumé

The present study demonstrated the development of gemcitabine and betulinic acid co-encapsulated PLGA-PEG polymer nanoparticles for enhancing the chemotherapeutic response. This combinatorial PLGA-PEG nanoparticle was formulated using double emulsion and had size <200 nm. The developed nanoparticles were characterized using dynamic light scattering and transmission electron microscopy for their size and shape, respectively. The in vitro release of the drugs from combinatorial nanoparticles was predominantly followed by Fickian diffusion phenomenon. Study on hemocompatibilty approved the administration of this combinatorial nanoparticle for animal study. In vitro cytotoxicity study on Panc1 cells using MTT assay, reactive oxygen species production and cellular apoptotic assay demonstrated that combinatorial nanoparticle was more cytotoxic compared to native drugs solution. Furthermore, the combinatorial nanoparticle suppressed tumor growth more efficiently in Ehrlich (solid) tumor model than the native gemcitabine and betulinic acid at the same concentrations. These findings indicated that PLGA-PEG nanoparticle might be used to co-deliver multiple chemotherapeutic drugs with different properties for enhancing antitumor efficacy.

Identifiants

pubmed: 30813082
pii: S0928-4931(18)32589-X
doi: 10.1016/j.msec.2019.01.026
pii:
doi:

Substances chimiques

Drug Carriers 0
Pentacyclic Triterpenes 0
Polyesters 0
Reactive Oxygen Species 0
Triterpenes 0
polyethylene glycol-poly(lactide-co-glycolide) 0
Deoxycytidine 0W860991D6
Polyethylene Glycols 3WJQ0SDW1A
Betulinic Acid 4G6A18707N
Gemcitabine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

764-771

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Ankit Saneja (A)

PK-PD Tox. & Formulation Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India; Product Development Cell-II, National Institute of Immunology, New Delhi, India.

Robin Kumar (R)

Product Development Cell-II, National Institute of Immunology, New Delhi, India.

Mubashir J Mintoo (MJ)

Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.

Ravindra Dhar Dubey (RD)

PK-PD Tox. & Formulation Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.

Payare Lal Sangwan (PL)

Natutal Product Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.

Dilip M Mondhe (DM)

Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India. Electronic address: dmmondhe@iiim.ac.in.

Amulya K Panda (AK)

Product Development Cell-II, National Institute of Immunology, New Delhi, India. Electronic address: amulya@nii.res.in.

Prem N Gupta (PN)

PK-PD Tox. & Formulation Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India. Electronic address: pngupta@iiim.ac.in.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH